Provided By PR Newswire
Last update: Nov 12, 2025
STATEN ISLAND, N.Y., Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2025.
Read more at prnewswire.comNASDAQ:ACXP (11/21/2025, 8:10:59 PM)
4.35
+0.44 (+11.25%)
Find more stocks in the Stock Screener


